New Skincare Standard in the GLP-1 Era: Molecular Nutrition from AV Laboratories
At the Aesthetic Medicine Congress in Monaco, a 360° molecular nutrition concept was introduced to support skin during weight loss amid the popularity of GLP-1 medications. AVL SOM3® technology with 20 amino acids targets collagen and elastin maintenance.
The Ozempic Face era is shifting into the Molecular Survival era: why AV Laboratories will change the rules faster than you think
You've heard of "Ozempic face"? Of course you have. In early 2026, photos of Hollywood stars with suddenly hollowed faces flooded global media—the result of taking GLP-1 agonists for rapid weight loss. While journalists debated the aesthetic disaster, the beauty industry quietly prepared its response. That response was unveiled on June 2, 2026, at the Aesthetic and Anti-Aging Medicine Congress (AMWC) in Monaco.
AV Laboratories, founded by pioneers in IVF and regenerative medicine, officially launched a concept that will become the standard for any premium skincare regimen within 12 months: 360° molecular skin nutrition based on the patented AVL SOM3® technology.
Why is this more than just another anti-aging cream with clever marketing? Because topical cosmetics have stopped acting as a "cosmetic bandage" and begun addressing the issue at the intersection of medicine and nutrition. 35% of patients on GLP-1 lose 15-20% of facial volume. Where dermatologists once offered fillers and threads (fixing the symptom, not the cause), AV Laboratories aims to prevent the skin from "dying" during the process.
[The Core]: What's Really Happening
A fundamental paradigm shift is underway: skin is no longer viewed as a decorative organ. The "apply cream and feel better" approach is fading. It is being replaced by a biomedical model that treats skin as tissue requiring specific metabolites to survive catabolic stress.
GLP-1 drugs (from Ozempic and Wegovy to newer oral forms) work through strict calorie restriction and metabolic changes. When the body faces an energy deficit, it reallocates resources: heart, brain, and liver come first. Skin and hair end up last in line. Moreover, up to 40% of lost weight comes from muscle mass rather than fat. Muscles serve as a metabolic reservoir of amino acids needed for collagen and elastin synthesis. No muscle means no building blocks for firmness.
What does AVL SOM3® do? The technology, developed by Ami and Monica Mezezi (founders of IVF clinics where every cell counts), delivers all 20 proteinogenic amino acids to the skin simultaneously. This is not an algae extract or a three-amino-acid peptide—it is a complete "building kit" for fibroblasts. The key word here is molecular.
The non-obvious insight: AV Laboratories does not create collagen. The company creates conditions under which skin can produce collagen itself, even when the body is starving on GLP-1. It is like supplying builders with materials when the cement factory has shut down. This changes the game because most anti-aging products merely stimulate fibroblasts to work faster—but what good is revving up a factory if no raw materials arrive?
Timeline and Context
To understand why June 2026 became the point of no return, consider three parallel tracks: medical, consumer, and industrial.
Medical track:
- 2005: FDA approves the first GLP-1 agonist.
- 2023: The term "Ozempic face" enters plastic surgeons' vocabulary. Dermatology Times notes a surge in patients complaining of a "sunken face" after rapid weight loss.
- April 2026: Journal of Clinical Medicine publishes a major review confirming that GLP-1 receptors are expressed in skin tissue, yet their role in aging remains "insufficiently clarified." This academic signal sparked the start of a "gold rush."
Consumer track (GlobalData data, March 2026):
- 10% of the adult US population is already taking GLP-1.
- 44% of large US companies have added weight-loss medications to employee insurance programs.
- Two-thirds of GLP-1 users have increased spending on vitamins and supplements.
- 35% of users report noticeable facial volume loss.
Industrial track (April–May 2026):
- April, Paris, In-Cosmetics Global 2026: Korean lab SC Labs presents a "skin-tightening" complex to restore elasticity lost to GLP-1 diets. Spanish company Provital announces the active Intensilk, targeting the hypodermis and "inducing calorie restriction" at the skin level.
- May, London: Boots and Superdrug chains aggressively stock Kind Patches appetite-management patches, confirming the trend toward "non-pill" solutions for metabolic health.
- June 2, 2026, Monaco, AMWC: AV Laboratories delivers a presentation that elevates the conversation from ingredients to therapeutic strategy.
Winners and Losers
Winners:
- AV Laboratories and companies with a "medical" background. The founders come from regenerative medicine and IVF—fields where "cell repair" is the profession. They carry no reputational baggage of "just cosmetics," which becomes a massive advantage in the GLP-1 era.
- Aesthetic clinics that revise their protocols. Dr. Anthony Rossi of Weill Cornell Medicine (co-author of the new post-GLP-1 rehabilitation guidelines) has stated: "Fillers do not solve laxity, collagen depletion, and crepiness." Clinics that begin selling not only injections but also AVL SOM3® "molecular support" courses will gain recurring revenue (30–60 days of use) instead of one-time procedures.
- Suppliers of amino acid complexes. The "GLP-1 beauty" market will grow from the current $5 billion (2023) to $100 billion by 2030 at a CAGR of 28%. This outpaces any other premium cosmetics segment.
Losers:
- "Clean beauty" brands built on fear of "chemistry." Their rhetoric that "natural = safe" collapses against the fact that when skin loses 20% of its volume in three months, rose water and shea butter will not help. Audiences are shifting to brands that speak the language of biology, not botany.
- Inert collagen supplement manufacturers. The drinkable collagen market, priced at $2–3 per dose, is now under pressure. Why ingest hydrolyzed collagen that has a 70% chance of breaking down into individual amino acids in the GI tract when you can deliver all 20 amino acids directly through the skin?
- Plastic surgeons relying solely on lifts. A patient who lost 30 kg on GLP-1 will visit a surgeon 12–18 months later, once the skin has adapted. Before that, they will spend $500–2000 on "molecular support" from a cosmetic dermatologist. Surgeons lose "early" patients and later compete for "residual" demand.
What the Media Is Not Saying
Media outlets write about "breakthrough," "innovation," and "future skincare." But no one mentions the enormous commercial interests of pharmaceutical giants or the delivery problem.
First, none of the coverage notes that Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro) are already negotiating to acquire or license technologies like AVL SOM3® long-term. This makes sense: pharma giants profit from obesity treatment but lose reputation on "Ozempic face." They benefit from having a "side-effect remedy." Right now it is cosmetics, but in 18 months it will be a Class II medical device with prescription amino acid complexes. AV Laboratories has essentially created a "crutch" for an industry that has altered the faces of millions.
Second, the question of bioavailability is downplayed. Claiming "we have 20 amino acids" is one thing. Proving they penetrate the stratum corneum into the dermis at therapeutic concentrations is another. AV Laboratories' press release mentions "patented technology" but says nothing about the penetration coefficient (Kp), nanoparticle size, or penetration enhancers. This is standard practice—make the promise and leave technical details for specialized journals six months later. In reality, synergy is likely at work: amino acids create an osmotic gradient that "pulls" moisture and actives into the upper layers, while deeper restoration occurs indirectly through improved barrier function.
Third, media overlook that the GLP-1 skin issue is not only volume loss. It also involves disrupted ceramide and cholesterol synthesis due to dietary fat deficiency. Neither 20 amino acids nor even filler injections restore the lipid barrier. AV Laboratories mentions "barrier resistance" as one of five pillars in its materials, yet lists no specific ingredients (ceramides, squalane, fatty acids) in the formula. This creates risk: the patient receives structural support, but the skin remains dry, sensitive, and prone to transepidermal water loss.
Forecast: Next 30 Days and 90 Days
Next 30 days (July 2026):
Western dermatology clinics will begin offering differentiated protocols for three stages of GLP-1 transformation:
- Pre-GLP-1 (4 weeks before starting) — AVL SOM3® course to build a "metabolic buffer" in the skin. Clinics that adopt this first will gain a competitive edge by showing "before/after" results with minimal "Ozempic face."
- Intra-GLP-1 (first 3–6 months) — combination of AVL SOM3® (morning/evening) with type III collagen inducers.
- Post-GLP-1 (after 12 months) — assessment of residual ptosis and decision on RF lifting or threads.
At the same time, expect a wave of "studies" from competitors claiming their formula is superior. Brands like SkinMedica, Alastin, and Zo Skin Health will issue urgent press releases about their "amino acid complexes," most containing only 5–8 amino acids (effective, but short of "all 20"). The market will enter an "amino acid war" phase, leaving consumers confused.
Next 90 days (Fall 2026):
The inevitable will occur: a peer-reviewed academic study (likely initiated by AV Laboratories or its partners) will confirm that topical application of the full amino acid profile reduces collagen loss rate on GLP-1 by 30–40% compared with placebo. This study will become the most-cited paper in "metabolic cosmetology."
Major retail chains (Sephora, Ulta, Boots) will dedicate separate shelves to "Metabolic Skincare" or "GLP-1 Support." AV Laboratories, SC Labs (Korea), Provital (Spain), and two or three US brands that manage to repackage older lines under the new narrative will occupy these shelves.
Prices for "molecular nutrition" will stabilize around $120–180 for a 30 ml serum. This exceeds mass-market pricing but costs less than a single dermatology session ($300–500). The subscription model (automatic delivery every 30 days) will become standard—because patients remain on GLP-1 for 12–18 months, and stopping "molecular support" leads to rapid deterioration.
Finally, and most importantly: Pharmaceutical companies will begin bundling GLP-1 with cosmeceuticals. Novo Nordisk will announce a partnership with a brand (not necessarily AV Laboratories, but one of similar stature), offering a "slimness and youthful face kit" with monthly delivery. This will be the moment of truth when cosmetics cease to be a "luxury" and become a medical consumable. AV Laboratories arrived at the right time and place, but the question remains: can they scale production to feed all the "hungry" GLP-1 patients? If not, pharmaceutical sharks will devour them within six months.
— Editorial Team
